DEF: Abpro Holdings Seeks Stockholder Approval for Share Issuance to Yorkville Under Standby Equity Purchase Agreement

Abpro Holdings is asking stockholders to approve the issuance of common stock to YA II PN, LTD. (Yorkville) under a Standby Equity Purchase Agreement to secure additional capital.

Summary

• Abpro Holdings, Inc. is holding a Special Meeting of Stockholders on April 8, 2025, to vote on two proposals.
• The first proposal seeks approval for the issuance of shares of common stock to YA II PN, LTD. (Yorkville) under a Standby Equity Purchase Agreement (SEPA), as required by Nasdaq Listing Rule 5635(d).
• The company entered into the SEPA with Yorkville on October 30, 2024, allowing Abpro to sell up to $50 million of common stock to Yorkville over a 24-month period.
• The issuance of shares may exceed 20% of the company's outstanding common stock, triggering the Nasdaq rule requiring stockholder approval.
• The second proposal requests approval to adjourn the Special Meeting if there are insufficient votes to approve the Yorkville Share Issuance Proposal.
• The Board recommends voting FOR both the Yorkville Share Issuance Proposal and the Adjournment Proposal.
• The record date for determining stockholders eligible to vote is March 14, 2025.
• The company has already issued 297,160 shares to Yorkville as a commitment fee, and these shares are not eligible to vote on the Yorkville Share Issuance Proposal.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting the facts of the proposed share issuance and the need for stockholder approval. While securing funding is generally positive, the potential dilution for existing shareholders tempers the overall sentiment.

Positives

• Approval of the Yorkville Share Issuance Proposal would provide Abpro with a reliable source of capital for general corporate purposes.
• The SEPA provides the company with future flexibility to enhance its liquidity in an opportunistic and efficient manner.
• The $2,000,000 Second Pre-paid Advance is conditioned upon, among other things, obtaining stockholder approval of the Yorkville Share Issuance Proposal.

Negatives

• Failure to approve the Yorkville Share Issuance Proposal would prevent the company from selling shares to Yorkville in excess of the Exchange Cap at less than the minimum price.
• The issuance of shares to Yorkville will dilute the percentage ownership interest of existing stockholders.
• The issuance of shares could dilute the book value per share of the common stock and may cause the market price of the common stock to decrease.

Risks

• If the Yorkville Share Issuance Proposal is not approved, Abpro may need to seek alternative sources of capital, which may not be available on favorable terms or at all.
• If the company is unable to raise additional capital, it may have difficulty executing its strategic plans and funding its operations.
• Depressed trading prices of the company's common stock could further impair its ability to raise sufficient capital.
• The company's ability to raise additional capital pursuant to its Standby Equity Purchase Agreement is not guaranteed.

Future Outlook

The company's ability to execute its strategic plans and fund its operations depends on raising additional capital, potentially through the SEPA with Yorkville. The company may need to seek alternative sources of capital if the Yorkville Share Issuance Proposal is not approved.

Management Comments

• The Board has determined that the SEPA and our ability to issue the shares of Common Stock thereunder in excess of the Exchange Cap and to draw on the $2,000,000 Second Pre-paid Advance are in the best interests of the Company and its stockholders because the ability to sell shares of Common Stock to Yorkville and access the additional $2,000,000 Second Pre-paid Advance provides us with a reliable source of capital for general corporate purposes.

Industry Context

Many small-cap biotech companies rely on equity financing to fund operations and research. Standby equity purchase agreements are a common tool for these companies to access capital, but they often require stockholder approval due to potential dilution.

Comparison to Industry Standards

• Similar agreements are used by companies like Mustang Bio and Cellectar Biosciences, which have also entered into SEPA agreements to secure funding.
• The terms of Abpro's SEPA, including the discount to market price and limitations on Yorkville's ownership, are generally consistent with industry standards for these types of agreements.
• The need for stockholder approval for exceeding a 20% share issuance is a standard requirement under Nasdaq rules, ensuring shareholder oversight of significant equity transactions.

Stakeholder Impact

• Approval of the Yorkville Share Issuance Proposal could benefit the company by providing access to capital, but it could also dilute the ownership interest of existing shareholders.
• Failure to approve the proposal could hinder the company's ability to raise capital and execute its strategic plans.

Next Steps

• Stockholders to vote on the Yorkville Share Issuance Proposal and the Adjournment Proposal at the Special Meeting on April 8, 2025.
• The company will file a Current Report on Form 8-K with the SEC to publish the voting results of the Special Meeting.

Key Dates

Keywords

Yorkville, share issuance, proxy statement, SEPA, Abpro Holdings, stockholder approval, capital, dilution